91 results about "Ribosomal RNA" patented technology

An isolated Bacillus amyloliquefaciens Ba-BPD1 having an Accession No. of DSM 21836 is provided. This novel strain has unique 16S ribosomal RNA sequenced as SEQ ID NO:1 and produces amylase, protease, cellulase and lipase, fibrinolytic enzyme to show their biodegradation capacities. Further, B. amyloliquefaciens Ba-BPD1 produces the antibiotic substances, such as iturin, fengycin and surfactin, and has antimicrobial capacity for inhibiting the fungal or bacterial growth. In conclusion, the novel strain of Bacillus amyloliquefaciens Ba-BPD1 and its products can be applied in agriculture, wastewater treatment, food industry and chemical industry.

Identification of microorganisms based on the sequences of their 5S, 23S and particularly 16S ribosomal RNAs is growing in utility as the database of known ribosomal RNA sequences expands. Experimental identification is usually based on matching the experimentally-determined sequence of an organisms rRNA to a previously-determined sequence in the databank, or hybridization of the organisms rRNA or encoding rDNA to an oligonucleotide probe specific for an organism anticipated to be present in the sample. Here we propose the identification of microorganisms based on the overall composition (not sequence or hybridization propensity) of characteristic molecules derived from their rRNA or rDNA sequences by enzymatic cleavage or localized amplification. Ribonuclease T1 fragments of rRNA composition determination by mass spectrometry are especially favored. The characteristic molecules used can be chosen to be “compositional signatures” whose presence/absence is known to be associated with particular groups of organisms.

The present invention provides methods, compositions and kits for the generation of next generation sequencing (NGS) libraries in which non-desired nucleic acid sequences have been depleted or substantially reduced. The methods, compositions and kits provided herein are useful, for example, for the production of libraries from total RNA with reduced ribosomal RNA and for the reduction of common mRNA species in expression profiling from mixed samples where the mRNAs of interest are present at low levels. The methods of the invention can be employed for the elimination of non-desired nucleic acid sequences in a sequence-specific manner, and consequently, for the enrichment of nucleic acid sequences of interest in a nucleic acid library.

embodiments of the invention include purification of DNA, preferably plasmid DNA, by use of selective precipitation, preferably by addition of compaction agents Also included is a scaleable method for the liquid-phase separation of DNA from RNA. RNA may also be recovered by fractional precipitation according to the invention. RNA, commonly the major contaminant in DNA preparations, can be left in solution while valuable purified plasmid DNA is directly precipitated. Endotoxin can also be kept to very low levels. The invention includes mini-preps, preferably of plasmid and chromosomal DNA to obtain sequenceable and restriction digestible DNA in high yields in multiple simultaneous procedures. As a method of assay, a labeled probe is precipitated by hybridizing it to a target, (erg. chromosomal DNA, oligonucleotides, Ribosomal RNA, tRNA), and thereafter precipitating the probe/target complex with compaction agents and leaving in solution any unhybridized probe.

An isolated Bacillus amyloliquefaciens Ba-BPD1 having an Accession No. of DSM 21836 is provided. This novel strain has unique 16S ribosomal RNA sequenced as SEQ ID NO:1 and produces amylase, protease, cellulase and lipase, fibrinolytic enzyme to show their biodegradation capacities. Further, B. amyloliquefaciens Ba-BPD1 produces the antibiotic substances, such as iturin, fengycin and surfactin, and has antimicrobial capacity for inhibiting the fungal or bacterial growth. In conclusion, the novel strain of Bacillus amyloliquefaciens Ba-BPD1 and its products can be applied in agriculture, wastewater treatment, food industry and chemical industry.

Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the presence of pathogen. Performing the method in the presence and absence of an antibiotic permits detection of antibiotic resistance.

The present invention provides methods and compositions, including kits, for the generation of cDNA from mRNA with reduced ribosomal RNA representation.

The present invention provides methods for selectively amplifying a target population of nucleic acid molecules (e.g., all mRNA molecules expressed in a cell type except for the most highly expressed mRNA species). The present invention also provides populations of oligonucleotides including the nucleic acid sequences set forth in SEQ ID NOS:1-933. These oligonucleotides can be used, for example, to prime the synthesis of cDNA molecules complementary to mRNA molecules isolated from mammalian blood without priming the synthesis of cDNA molecules complementary to globin mRNA, or ribosomal RNA molecules.

The invention provides human protein complexes with endonuclease activity. In particular, the invention provides human protein complexes with tRNA splicing endonuclease activity and/or 3' end pre-mRNA endonuclease activity. The invention also provides a splice variant of human Sen2, namely human Sen2deltaEx8, and human protein complexes comprising human Sen2deltaEx8. The human Sen2deltaEx8 complexes have pre-tRNA cleavage activity and/or 3' end pre-mRNA endonuclease activity. The invention also provides human protein complexes with pre-ribosomal RNA cleavage activity. The invention also provides antibodies that immunospecifically bind to a complex described herein or a component thereof, and methods of diagnosing, preventing, treating, managing or ameliorating a disorder utilizing such antibodies. The present invention also provides methods utilizing the complexes described herein, inter alia, in screening, diagnosis, and therapy. The invention further provides methods of preparing and purifying the complexes. The present invention further provides methods of identifying a compound that modulates the expression of a component of a complex described herein, the formation of a complex described herein or the activity of a complex described herein, and methods of preventing, treating, managing or ameliorating a disorder, such as a proliferative disorder, or a symptom thereof utilizing a compound identified in accordance with the methods.

Methods of obtaining a sample of target nucleic acid from cells containing the target nucleic acid and genomic DNA or RNA are disclosed. In contrast to prior art protocols, this method does not require the cells containing the target nucleic acid to be lysed and instead is based on the observation when cells are suspended in an aqueous medium and the target nucleic acid are released into the medium through the cell walls. The invention therefore helps to avoid the use of cell lysis, heating, extremes of pH, water immiscible solvents, and electrical fields used in prior art nucleic acid extraction methods. The present invention is particularly applicable to the separation of non-genomic nucleic acid, such as cellular vector DNA or RNA, self-replicating satellite nucleic acids or plasmid DNA, from genomic nucleic acids, such as host cell chromosomes and ribosomal RNA.

The invention discloses a method for constructing Ribo-seq sequencing libraries. The method includes separating Ribosome-nascent chain complexes (RNC); carrying out enzyme digestion on the RNC; directly constructing the libraries without rRNA [ribosomal RNA (ribonucleic acid)] removal; selecting RPF (ribosome protected fragments) bands and carrying out sequencing on RPF. The method has the advantages that rRNA does not need to be removed, accordingly, expensive rRNA removal reagent kits can be omitted, optional species can be coped, and the method is wide in application range; RPF reads proportions of the method are higher than RPF reads proportions of the traditional methods, the flux requirements can be lowered, and accordingly the sequencing cost can be lowered.

The invention discloses a ribosomal RNA sequence of a pathogenic bacterium Septoria sp of an oak abnormally withered disease and application thereof. The nucleotide sequence of the ribosomal RNA geneof the pathogenic bacterium Septoria sp of the oak abnormally withered disease is shown as SEQ ID NO.1, and the sequence can be utilized to detect the pathogenic bacterium Septoria sp of the oak abnormally withered disease and can also be applied to research on the classification of fungal species. In addition, the invention also provides a primer for detecting the pathogenic bacteria Septoria spof the oak abnormally withered disease. The primer has good specificity, a specific detection method and a specific detection kit are established based on the primer, the required detection time is short, the detection is rapid and efficient, and the primer has a good application prospect in detection of the pathogenic bacteria Septoria sp of the oak abnormally withered disease.

The present invention relates to a process for producing zeaxanthin, β-carotene, or lycopene, comprising inducing mutation in a carotenoid-producing microorganism in which the base sequence of DNA corresponding to 16S ribosomal RNA is substantially homologous to the base sequence described in SEQ ID NO: 1; screening for a mutant strain having a high product proportion of zeaxanthin, β-carotene, or lycopene to the whole production amount of carotenoids to provide a microorganism producing zeaxanthin, β-carotene, or lycopene; culturing the mutant microorganism; and harvesting zeaxanthin, β-carotene, lycopene or a carotenoid mixture containing the same from the resultant culture.

The invention discloses a method for construction of a transcriptome sequencing library. The method comprises the following steps: providing a DNA molecule containing to-be-removed rRNA; carrying outdesigning on account of a DNA sequence of the to-be-removed rRNA so as to obtain a Crispr RNA pool; and allowing a DNA sample to contact with the Crispr RNA pool and Crispr protein so as to obtain a sample compiled by a Crispr system and obtain the transcriptome sequencing library and a kit used for construction of the transcriptome sequencing library. The method and the kit provided by the invention can remove a large number of redundant RNA like rRNA with high efficiency, enrich other molecules in the sample, improve the data quality and the effective data ratio of initial transcriptome sequencing, and reduce the cost of sequencing.

The invention generally relates to compositions for maximizing capture of affinity-labeled molecules on solid supports. The disclosed methods and compositions were developed to maximize depletion of ribosomal RNA from total RNA samples, which is useful to improve the quality of RNA preparations used for applications such as massively parallel sequencing. The RNA depletion method is based on using long affinity-labeled RNA molecules that are complementary to all or part of the target ribosomal RNAs, as subtractive hybridization probes.

The invention relates to a multiple-gene detecting kit related to antitumor drugs. The multiple-gene detecting kit comprises a mixture of RT (reverse transcription) primers and a mixture of PCR (polymerase chain reaction) amplification primers, wherein each RT primer and each PCR amplification primer based on genetic groups, reference genes and a reaction internal label are respectively contained in each of the mixture of the RT primers and the mixture of the PCR amplification primers; the multiple-gene detecting kit is characterized in that the genetic groups comprise PTEN, EGFR, DPYD, HER2, RRM1, ERCC1, TUBB3, TOP1, TYMS and TOP2A; the reference genes comprise ACTB, GAPDH and B2M; the reaction internal label is KAN-rRNA (ribosomal RNA). The multiple-gene detecting kit related to antitumor drugs disclosed by the invention can be used for systemically detecting the expression level of a plurality of genes closely related to the antitumor drugs by one step, is simple and convenient to use, good in accuracy and high in detecting efficiency, and can be used for guiding chemotherapy drugs and selecting chemotherapy regimens very well.

The invention discloses an intestinal flora for diagnosing sarcopenia and application of the intestinal flora. The intestinal flora is Eisenbergiella. Through 16S ribosomal ribonucleic acid sequencing, the situation that Eisenbergiella is remarkably increased in sarcopenia is found for a first time, the situation that high specificity and sensitivity can be achieved when sarcopenia and healthy people are distinguished by using Eisenbergiella as a detection variable is further found, so that on the basis, Eisenbergiella can be applied to noninvasive diagnosis on sarcopenia.

The invention belongs to the technical field of medical detection, in particular relates to a nucleic acid amplification detection method for distinguishing DNA from correspondingly transcribed RNA and provides a corresponding detection kit. The kit comprises pyrolysis solution, nucleic acid extracting solution, lysozyme solution, reverse transcription buffer solution, a reverse transcriptase system, tuberculosis DNA PCR reaction solution, tuberculosis RNA PCR reaction solution and the like, wherein selected primers aim at a section of ITS sequence or IS6110 sequence and a section of 16S rRNA sequence on ribosomal RNA respectively; and a probe is Tagman MGB probe preferably and labeled by different fluorescein. The kit comprises a glycosidase (UNG) component, can judge the relative 16S rRNA content of each bacterium and is used for judging the growth condition of mycobacterium tuberculosis in a sample so as to monitor infection state. The kit is simple, convenient and fast, can specifically detect the RNA and DNA and provides more comprehensive information for clinical use.

The invention provides a method of separating non-ribosomal transcribed RNA (nrRNA) fragments from ribosomal RNA (rRNA) and rRNA fragments. The method comprises (i) providing a sample comprising rRNA, rRNA fragments, and nrRNA fragments, and (ii) providing a plurality of probes. The probes hybridize to RNA targeting sequences of at least 50% of the contiguous regions of the rRNA and to rRNA fragments comprising the rRNA targeting sequences. The method further comprises (iii) adding the plurality of probes to the sample, (iv) hybridizing the probes to the rRNA and rRNA fragments to form rRNA-probe complexes and rRNA fragment-probe complexes, and (v) separating the rRNA-probe complexes and rRNA fragment-probe complexes. The invention also provides a method of amplifying an nrRNA fragment, a method of analyzing nrRNA expression, a method of determining the level of nrRNA in a sample, and a kit and system useful in any of the foregoing methods.

The present invention describes a method for detecting the presence and type of a microorganism present in a sample by means of stabilization and sequencing techniques and subsequent analysis of microsequences in genes encoding the ribosomal RNA most conserved, and on specific areas of the 16-S region with taxonomic value.

The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.